Review Special Issues

Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases

  • Sphingosine 1-phosphate (S1P), a multi-functional phospholipid mediator, is generated from sphingosine by sphingosine kinases and binds to five known G protein-coupled S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5). It is widely accepted that S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from the secondary lymphoid organs (SLO) and thymus, because lymphocyte egress from these organs to periphery is at extremely low levels in mice lacking lymphocytic S1P1. Fingolimod hydrochloride (FTY720) is a first-in-class, orally active S1P1 functional antagonist which was discovered by chemical modification of a natural product, myriocin. Since FTY720 has a structure closely related to sphingosine, the phosphorylated FTY720 (FTY720-P) is converted by sphingosine kinases and binds 4 types of S1P receptors. FTY720-P strongly induces down-regulation of S1P1 by internalization and degradation of this receptor and acts as a functional antagonist at S1P1. Consequently, FTY720 inhibits S1P1-dependent lymphocyte egress from the SLO and thymus to reduce circulating lymphocytes including autoreactive Th17 cells, and is highly effective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In relapsing remitting MS patients, oral FTY720 shows a superior efficacy when compared to intramuscular interferon-β-1a. Based on these data, it is presumed that modulation of the S1P-S1P1 axis provides an effective therapy for autoimmune diseases including MS.

    Citation: Kenji Chiba, Yasuhiro Maeda, Noriyasu Seki, Hirotoshi Kataoka, Kunio Sugahara. Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases[J]. AIMS Molecular Science, 2014, 1(4): 162-182. doi: 10.3934/molsci.2014.4.162

    Related Papers:

    [1] Ciro D'Apice, Peter Kogut, Rosanna Manzo . On generalized active contour model in the anisotropic BV space and its application to satellite remote sensing of agricultural territory. Networks and Heterogeneous Media, 2025, 20(1): 113-142. doi: 10.3934/nhm.2025008
    [2] Julien Barré, Pierre Degond, Diane Peurichard, Ewelina Zatorska . Modelling pattern formation through differential repulsion. Networks and Heterogeneous Media, 2020, 15(3): 307-352. doi: 10.3934/nhm.2020021
    [3] Tong Li . Qualitative analysis of some PDE models of traffic flow. Networks and Heterogeneous Media, 2013, 8(3): 773-781. doi: 10.3934/nhm.2013.8.773
    [4] Ling Zhang, Xuewen Tan, Jia Li, Fan Yang . Dynamic analysis and optimal control of leptospirosis based on Caputo fractional derivative. Networks and Heterogeneous Media, 2024, 19(3): 1262-1285. doi: 10.3934/nhm.2024054
    [5] Panpan Xu, Yongbin Ge, Lin Zhang . High-order finite difference approximation of the Keller-Segel model with additional self- and cross-diffusion terms and a logistic source. Networks and Heterogeneous Media, 2023, 18(4): 1471-1492. doi: 10.3934/nhm.2023065
    [6] Ivano Primi, Angela Stevens, Juan J. L. Velázquez . Pattern forming instabilities driven by non-diffusive interactions. Networks and Heterogeneous Media, 2013, 8(1): 397-432. doi: 10.3934/nhm.2013.8.397
    [7] Wenkai Liu, Yang Liu, Hong Li, Yining Yang . Multi-output physics-informed neural network for one- and two-dimensional nonlinear time distributed-order models. Networks and Heterogeneous Media, 2023, 18(4): 1899-1918. doi: 10.3934/nhm.2023080
    [8] Ming-Kai Wang, Cheng Wang, Jun-Feng Yin . A second-order ADI method for pricing options under fractional regime-switching models. Networks and Heterogeneous Media, 2023, 18(2): 647-663. doi: 10.3934/nhm.2023028
    [9] Jinhu Zhao . Natural convection flow and heat transfer of generalized Maxwell fluid with distributed order time fractional derivatives embedded in the porous medium. Networks and Heterogeneous Media, 2024, 19(2): 753-770. doi: 10.3934/nhm.2024034
    [10] Jean-Marc Hérard, Olivier Hurisse . Some attempts to couple distinct fluid models. Networks and Heterogeneous Media, 2010, 5(3): 649-660. doi: 10.3934/nhm.2010.5.649
  • Sphingosine 1-phosphate (S1P), a multi-functional phospholipid mediator, is generated from sphingosine by sphingosine kinases and binds to five known G protein-coupled S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5). It is widely accepted that S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from the secondary lymphoid organs (SLO) and thymus, because lymphocyte egress from these organs to periphery is at extremely low levels in mice lacking lymphocytic S1P1. Fingolimod hydrochloride (FTY720) is a first-in-class, orally active S1P1 functional antagonist which was discovered by chemical modification of a natural product, myriocin. Since FTY720 has a structure closely related to sphingosine, the phosphorylated FTY720 (FTY720-P) is converted by sphingosine kinases and binds 4 types of S1P receptors. FTY720-P strongly induces down-regulation of S1P1 by internalization and degradation of this receptor and acts as a functional antagonist at S1P1. Consequently, FTY720 inhibits S1P1-dependent lymphocyte egress from the SLO and thymus to reduce circulating lymphocytes including autoreactive Th17 cells, and is highly effective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In relapsing remitting MS patients, oral FTY720 shows a superior efficacy when compared to intramuscular interferon-β-1a. Based on these data, it is presumed that modulation of the S1P-S1P1 axis provides an effective therapy for autoimmune diseases including MS.


    The temporal-parietal junction (TPJ) is a region of the cerebral cortex placed on the border between the temporal and parietal lobes [1]. TPJ is a key hub for a wide range of processes and functions, including: 1) the integration of multisensory-related information [2] and visuospatial perspective taking [3]; 2) self-processing, such as sense of agency [4], self-other distinction and mental own-body imagery [2]; 3) embodiment (the sense of being localized within one's physical body) which is a fundamental aspect of the self [5]. On the contrary, the feeling of disembodiment, as well as the lack of sense of agency or body perceptual distortions/illusions can be experienced in particular states or conditions. The disembodiment is a prominent feature in specific dissociative disorders, namely depersonalization/derealization disorders (DPD). DPD has been estimated to be present in 1–2% of the general population, however empirical evidence suggests that it is severely underdiagnosed [6]. According to DSM-5 [7], DPD is characterized by perceptual alteration in experience toward the integrity of self (phenomenon called depersonalization referred to a feeling of detachment from one's own senses and body) and the surrounding environment (phenomenon known as derealization, a feeling of unreality toward people and objects around) [8]. Moreover, transient episodes of DPD can be found in particular states, such as fatigue and fear [9], as well as in comorbidity with a wide range of psychiatric and neurological conditions [10], such as temporal lobe epilepsy [11], schizophrenia [12], or posttraumatic stress disorder (PTSD) [13]. Physiological and neuroimaging studies have demonstrated neurobiological alterations in the temporal regions in patients with DPD [14], however other studies underlined a fronto-limbic imbalance along with hyperactivity of prefrontal structures and hypoactivation of limbic regions [15][17]. A recent line of research suggests that typical symptoms of DPD may be caused by an altered functional connectivity, that may explain the cognitive and emotional disconnection in dissociation [18]. For these reasons, it is possible to hypothesize that brain regions with a key role in sensory integration and sense of self, such as TPJ, may concur to DPD symptomatology. Interestingly, the feeling of disembodiment, as well as the lack of sense of agency or body perceptual distortions and illusions, can be induced experimentally using specific protocol to induce body illusions. For example, the rubber hand illusion paradigm is one of the most well-known procedures to create body distortions and can be used to enhance an illusion of lack embodied self [19]. Amongst others, the most extreme condition in which a depth sense of disembodiment occurs is the Out of Body Experience (OBE), defined as the experience in which a person seems to be awake and to see his body and the world from a location outside his physical body, due to an abnormal sense of spatial unity between the self and the body [20],[21]. Specific experimental methods allow to induce a type of body illusions as a tool to reshapes the boundaries of body and peripersonal representations such as the distinction in which the external between what may or may not be part of the own body (or the distinction between it and external, non-corporeal, objects) [22] and the real perception of one's own body and that of others [23]. One of these experimental methods used to induce body illusion and distortions is the Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive brain stimulation technique allowing the induction of magnetic currents in depth, through the modification of the underlying neural activity [24],[25]. In particular, TMS induces a magnetic field on the scalp, resulting in a depolarization of neuronal tissue and a generation of action potentials [26]. Variables to be considered for a correct use of the TMS are the following: i) stimulation repetition modes: the main stimulation repetition modes include repetitive stimulators (rTMS). rTMS protocols at low frequency (1 Hz) produces a decrement in cortical excitability, while high frequency, usually ranged between 5 and 20 Hz produces its increment [27],[28]. In addition to the conventional rTMS, patterned stimulation protocols have been introduced (i.e., theta burst stimulation). However, the differentiation between decrement and increment of cortical excitability is not well-demarked, since an important degree of inter-individual variability is reported (i.e., inhibitory effect at high frequency rTMS and facilitatory effect at low frequency modulation [29],[30]: for this reason, the concept of functional lesion, the transient and reversible disruption of functionality induced by 1 Hz, has been questioned [31]. It can stimulate up to single pulse in a second [32],[33]; ii) risetime: this term refers to the time taken for a magnetic (or electrical) stimulation pulse to reach its peak amplitude [34]; iii) coil geometry and position: since a focal stimulation could not be delivered, areas that are associated with a specific function are stimulated. The geometry of the coil and its position involve different magnetic fields with specific characteristics [35]; iv) brain depth penetration: it is dependent from coil geometry and size, local anatomy, stimulus strength, and perhaps even gravitational effects on the brain within the skull space [36]; v) safe stimulator design: important the amount of energy involved and the speed with which the energy is delivered [26]. Promising results in adult neurologic and psychiatric disorders are driving active research into transcranial brain stimulation techniques, particularly TMS and transcranial direct current stimulation (tDCS) [37][40].

    TMS protocols seem to effectively treat a wide range of psychiatric disorders such as mood disorders, schizophrenia, and obsessive-compulsive disorders [41]. In recent times, a few studies have started to investigate the effectiveness of TMS in enhancing an embodied state of consciousness [42],[43].

    This systematic review aims to demonstrate the importance of TPJ as “core structure” in functional networks underlying the bodily construction of self, taking into account specific clinical conditions such as DPD and healthy controls subjected to body distortions experimental protocols. Additionally, the present study investigates whether the use of TMS could support the treatment of DPD and other clinical conditions in which depersonalization and derealization are displayed. Finally, we discuss the neural bases underlying the awareness of the body self-awareness.

    This systematic review includes studies of any sham or controlled trial type design which incorporated outcomes concerning the application of TMS on TPJ in functional consciousness disorders such as DPD, but also the experimental induction of illusions (Out-of-Body Experience, Mirror Box Illusion, Rubber end and Body perceiving). Studies were included if the following inclusion criteria were met: (1) participants diagnosed with DPD and healthy participants; (2) stimulation via TMS; (3) TPJ stimulation, (4) human subjects; (5) patients over 18 years old; (6) single or repeated TMS sessions; (7) publications in English language. From the retained selection, we excluded: (1) duplicates; (2) non-human subjects, (3) TMS targeting other areas than TPJ; (4) reviews and (5) irrelevant studies after title/abstract screening. The search strategy was conducted in September 2020 and the publication date was not limited. To identify suitable publications, an online search of the PubMed, Cochrane Library, Web of science and Scopus, databases was performed using specific search terms “TMS” AND “temporoparietal junction” AND “self”, “TMS” AND “temporoparietal junction” AND “awareness”, “TMS temporoparietal junction” AND “depersonalization”, “TMS” AND “temporoparietal junction” AND “derealisation”, “TMS temporoparietal junction” AND “body”. Three independent reviewers (GO, VC, DB) performed the screening of the articles based on title and abstract. Duplicates were checked and removed using Mendeley desktop reference manager (http://www.mendeley.com). A visual independent check of duplicates was performed to ensure the complete removal of duplicates. Additionally, review articles and the references section of each article included in the study was checked to find additional hits satisfying the inclusion criteria according to the purpose of this review.

    Our search identified a total of 108 records through multiple databases searching and 1 additional record identified through other sources (Table 1).

    After duplicates removal, 38 hits were screened (Figure 1). After title and abstract reading, we retained a total of 16 records for the assessment of eligibility. According to our inclusion criteria, we retained 8 studies for a qualitative synthesis.

    Table 1.  Search strategy, databases, date of access and MESH terms.
    Database Date of Search MeSH Terms Results
    TMS TMS TMS TMS TMS
    temporoparietal junction self temporoparietal junction and awareness temporoparietal junction and depersonalization temporoparietal junction and derealization temporoparietal junction body
    Pubmed 16/09/2020 14 5 3 2 7 31
    Cochrane Library 16/09/2020 11 4 3 1 0 19
    Web of Science 16/09/2020 16 4 0 1 12 33
    Scopus 16/09/2020 11 4 3 0 7 25
    Total Results 108

     | Show Table
    DownLoad: CSV
    Figure 1.  Prisma flow chart of study selection.

    The selected articles were classified into two sub-categories: the first containing the application of TMS on TPJ for reducing the feeling of disembodiment for therapeutic purposes in DPD patients (4 studies); the second concerning the application of TMS on TPJ for inducing the feeling of disembodiment to neurophysiological and theoretical purposes (illusion) (4 studies).

    We investigated the effects of TMS targeting TPJ in subjects with DPD or subjects with numbness, feeling of unreality, feeling of detachment from oneself/surrounding (Table 2). Specifically, all the studies used repetitive transcranial magnetic stimulation (rTMS).

    Table 2.  Experimental Illusion for disembodiment induction.
    Author S Sample (N) Stimulation Coil Frequency Pulses Session Measures Procedure Coil Position/Method Outcome
    Mantovani et al., 2011 [43] N = 12 rTMS (Magstim Super-rapid stimulator) Fo8 (70 mm) 1 Hz 800 per session 3 weeks plus 3 weeks (30–42 sessions; not stated) CADSS, HDRS, HARS, CGI-S, CDS, DES, BDI–II, Zung-SAS, PGI Baseline and after each week rTPJ or lTPJ, between T4/P4 and T3/P3 respectively, according to 10–20 EEG System After 3 weeks, 6 out of 12 patients responded. Five responders have received 3 more weeks of rTPJ-rTMS showing 68% DPD symptoms improvement
    Christopeit et al., 2014 [44] N = 12 rTMS (Magstim Super-rapid stimulator) Fo8 (70 mm) 1 Hz 800 per session 3 weeks plus 3 weeks (30–42 sessions; not stated) CADSS, HDRS, HARS, CGI-S, CDS, DES, BDI–II, Zung-SAS, PGI Baseline and after each week rTPJ or lTPJ, between T4/P4 and T3/P3 respectively, according to 10–20 EEG System Reduction in anomalous body experiences, alienation from surroundings, anomalous subjective recall and emotional numbing
    Jay et al., 2014 [45] N = 37 rTMS (Magstim Rapid2) NA 1 Hz 900 1 CDS, BDI, BAI, DES, skin conduction, subjective arousal Pre/post rTMS, phone interview 24 h post rTMS rVLPFC, neuronavigated Increase of electrodermal capacity. DD patients showed increased SFs of skin conductance post rTMS. Both rVLPFC and rTPJ-rTMS showed a reduction in DDS
    Wulf et al., 2019 [46] N = 4 rTMS NA Cond.1 = 1 Hz Cond.2 = 1 Hz Cond.1 = 1800 pulses
    Cond.2 = 900 pulses
    15 rTMS stimulation over three weeks NA Baseline and after 6-week Cond.1 = temporoparietal junction (TPJ)
    Cond.2= right ventrolateral prefrontal cortex (rVLPFC)
    Reduction of symptoms of rTMS over TPJ
    Reduction of symptoms in 6-week-FU rating compared to baseline (TMS over rVLPFC)

    Notes: BAI: Beck Anxiety Inventory; BDI-II: Beck Depression Inventory; BS: between subject; CADSS: Clinician-Administered Dissociative States Scale; CBT: cognitive- behavioral-therapy; CDS: Cambridge Depersonalization Scale; CGI-S: Clinical Global Impression-Severity; Cond: Condition; DDS: Depersonalization-derealization-syndrome; DES: Dissociative Experiences Scale; DPD: depersonalization disorder; EEG: Electroencephalogram; FU: follow-up; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; lTPJ: left temporoparietal junction; NA: not available; PGI: Patient Global Impression; rIPS: right intraparietal sulcus; rTMS: transcranial magnetic stimulation; rTPJ: right temporoparietal junction; rVLPFC: right ventrolateral prefrontal cortex; SFs: spontaneous fluctuations; TPJ: temporoparietal junction; Zung-SAS: Zung- Self Administered Scale.

     | Show Table
    DownLoad: CSV
    Table 3.  Experimental Illusion for disembodiment induction.
    Author S Sample (N) Stimulation Coil Frequency Pulses Session Measures Procedure Coil Position/Method Outcome
    Blanke, 2005 [42] N = 11 rTMS (Magstim Rapid stimulator) Fo8 (70 mm) 1 Hz 900 4 (2 sessions per day for 2 days) Average RTs of correct responses Pre and Post rTMS rEBA and TPJ in different sessions Selective activation of the TPJ (at 330–400 ms after stimulus onset) during the imagery task that resemble OBE
    Tsakiris et al., 2008 [22] N = 10 Single pulse erTMS (2T Magstim 200) Fo8 (70 mm) ER 160. One per trial (350 ms after stimuli) 1 Proprioceptive drift (cm) Each trial, post stimulus and TMS (after 3350 ms) rTPJ (Mean MNI = 63.4, −50, 22.7). TPJ defined as intersection of SMG, AG and STG TMS applied over rTPJ influenced proprioceptive drifts
    Papeo et al., 2010 [47] N = 14 Single pulse erTMS (Magstim 200) Fo8 (70 mm) ER One per trial (350 ms post stimuli) 1 Accuracy and RT on congruent and incongruent trials Within 3 s of each stimulus application rTPJ (Mean MNI: 63.4, −50.0, 22.7; intersection of SMG, AG and STG), neuronavigated based on prior MRI data Poor accuracy for digit 4 compared to digit 3, particularly when incongruent.
    Improved accuracy for digit 4 incongruent trials
    Reduced conflicting visual information after TMS
    Cazzato et al., 2014 [23] N = 66 rTMS (Magstim Rapid) Fo8 (70 mm) 1 Hz 900 3 (TPJ, EBA, no-TMS) Body distortion score; object distortion score Pre- and post-rTMS rEBA, rTPJ (Talairach = 63, −50, 23) The outcomes detected showed that the stimulation of rTPJ leads to an overestimation bias when the subjects had to make judgments about other people' body. This effect is more consistent in right EBA than in left EBA, greater in women than in men

    Notes: AG: angular gyrus; EBA: extrastriate body area; no-TMS: not TMS; MNI: Montreal Neurological Institute coordinate system; OBE: out of body experience; rEBA: right extrastriate body area; rTMS: transcranial magnetic stimulation; rTPJ: right temporoparietal junction; RTs: reaction times; SMG: right supramarginal gyrus; STG: superior temporal gyrus; TPJ: temporoparietal junction.

     | Show Table
    DownLoad: CSV

    Mantovani et al. [43], investigated the effect of inhibitory low frequency rTMS over the right TPJ (rTPJ) for three weeks, the right TPJ of 12 outpatients was targeted. During the following three weeks, the six outpatients who responded positively were stimulated on the same targeted area. In this regard, an improvement of 68% (F = 8.81; df = 6; p = 0.000) in DPD symptoms were shown. Moreover, partial/non-responders were stimulated on the left TPJ (lTPJ), but no significant improvement of DPD symptoms was shown. Based on the results obtained by Mantovani et al. [43], Christopeith and colleagues [44] conducted a retrospective analysis on data excerpts from the study. They have divided the scores derived by the Cambridge Depersonalization Scale (CDS) on the following symptoms clusters: reductions in anomalous body experiences, alienation from surroundings, emotional numbing, and anomalous subjective recall. After three weeks stimulation of rTPJ, significant reductions of anomalous body experiences (50% improvement; F = 4.7; df = 3; p = 0.008) and anomalous subjective recall (22% improvement; F = 3.1; df = 3; p = 0.041) were detected. Whereas after six weeks of rTMS, an additional significant reduction in anomalous body experiences (76% improvement; F = 5.1; df = 6; p = 0.002) and alienation from the surrounding environment (54% improvement; F = 3.1; df = 6; p = 0.023) were found. Moreover, a clinical, but non-significant improvement in emotional numbing (52% reduction; F = 2.4; df = 6; p = 0.057) and anomalous subjective recall were found (57% improvement; F = 1.9; df = 6; p = 0.115).

    Jay and colleagues [45] tested the effect of 1 Hz rTMS targeting ventrolateral prefrontal cortex (VLPFC) or TPJ on patients affected by medication resistant DPD. To this purpose, measures maximum skin conductance capacity, as well as the CDS for the assessment of symptomatology were employed. Moreover, a secondary outcome included spontaneous fluctuations (SFs) and event-related skin conductance responses. Results shown a reduction of symptoms after both conditions (t = −2.2; df = 19; p = 0.04), but only after rTMS targeting VLPFC, an increase of electrodermal capacity, namely maximum skin conductance deflections, was reported (t = −2.2; df = 7; p < 0.05). No change in event-related electrodermal activity was detected after rTMS protocol.

    Recently, Wulf et al. [46] adopted the protocol used by Mantovani et al. [44] for the stimulation of right VLPFC, whereas for the stimulation of right TPJ the authors used the protocol employed by Jay et al. [45]. At the same time, all the patients received Cognitive Behavioral Therapy (CBT) comprising interventions such as mindfulness, confrontation, muscle relaxation and sports. After six weeks, a follow up evaluation highlighted the ameliorating effects of combined CBT-TMS treatment on DPD.

    The use of TMS on TPJ in healthy volunteers, can enhance the feeling of disembodiment, altered the boundaries of body and the capacity for proprioception and lead to alterations in the evaluation of multisensory conflicts and in the evaluation of one's own or others' body (Table 3).

    Blanke et al. [42], investigated the role of TMS over TPJ to induce OBE in a group of 11 healthy volunteers. Using evoked potential mapping, authors showed the selective activation of the TPJ at 330–400 ms after stimulus onset when healthy volunteers imagined themselves in the position and visual perspective that generally are reported by people experiencing spontaneous OBEs. In this study, it has been found that TMS over TPJ impaired mental transformation of one's own body in healthy volunteers (F = 24.4; p = 0.003) relative to TMS delivered over a control site located on the intraparietal sulcus (IPS) (F = 2.16; p = 0.19).

    In order to investigate the role of the rTPJ in preserving a coherent body ownership, Tsakiris and colleagues [22] tested the effect of proprioceptive judgment (drift) after a four-block trial in which rTPJ or the vertex (as control site) were stimulated 350 ms after visuo-tactile synchronous stimulation, while the subjects were viewing either a rubber hand or neural object. Additionally, participants performed two further blocks viewed either the rubber hand or neutral object while receiving asynchronous stroking, without TMS stimulation. The results of the study showed that TMS over the rTPJ decreases the incorporation of the rubber hand into the mental representation of one's own body (t = 4.67; p < 0.05; two-tailed). On the contrary, authors found an increment incorporation of a neutral object (t = 2.55, p < 0.05, two-tailed).

    To investigate the role of rTPJ in intersensory conflicts, Papeo et al. [47] used a single pulse TMS delivered 350 ms after visuotactile stimulation in the mirror-box illusion. Results showed a reduced accuracy in localizing the left touch for the ring finger rather than the middle finger in the incongruent trials (F = 8.250; p < 0.02). After TMS, an improvement of accuracy indexes for ring finger in incongruent trials was found, suggesting the role of rTPJ in detecting (p = 0.01), rather than resolving, multisensory conflicts.

    The role of TPJ and extrastriate body area (EBA; located at the posterior inferior temporal sulcus/middle temporal gyrus) in perceiving one's own body and others body has been investigated by Cazzato and colleagues [23] in which a body distortion technique combined with rTMS stimulation was used. Participants had to judge the size readjustments on images of their own or other bodies, both from a subjective or intersubjective perspective. The outcomes detected showed that the stimulation of rTPJ leads to an overestimation bias when the subjects had to make judgments about other people' body (F = 4.009; p = 0.025). This effect was more consistent in right EBA than in left EBA, greater in women than in men. A strong lateralization of the right hemisphere of the active role of the EBA in aesthetic judgments is therefore observed in women, but less in men.

    This review analysed the efficacy of TMS targeting TPJ in patients with DPD and the illusion of disembodiment induced in healthy subjects. TPJ is hypothesized to be a core hub for an embodied concept of consciousness. TMS stimulation on TPJ in patients with symptoms of depersonalization and derealization leads to an improvement in the severity of the symptoms. On the other hand, the application of the TMS on TPJ in healthy patients can induce phenomena of illusion perception of self. The studies included in this review showed a significant reduction of symptoms in DPD patients treated with inhibitory low frequency rTMS over rTPJ for three weeks [43],[45], as well as a notable reduction of anomalous body experiences [44]. A six-week CBT-TMS combination treatment in DPD patients resulted in a significant improvement in symptoms such as depersonalization and derealization [46]. Likewise, the application of TMS on TPJ in healthy volunteers, through specific experimental procedures, may induce body illusions. For instance, it was demonstrated that the application of TMS on TPJ impaired mental transformation of one's own body [42], proprioceptive abilities [22] and the resolution of intersensory conflicts [47]. Furthermore, Cazzato et al. [23] observed difference between man and woman in the hemispheric asymmetry of EBA region, in the aesthetic processing of human bodies. Women have more dominance of the right hemisphere than men.

    Taken collectively, the results of the considered studies showed evidence of the positive effects of TMS on TPJ or between temporal and parietal regions (in particular, T4/T3 and T3/P3) in patients with a diagnosis of DPD. The results need to be implemented with further scientific evidence. Some studies pointed out a large-scale neural integration as the basis of a correct perception of the body self [18]. In fact, neuroimaging research has shown a fronto-limbic imbalance in DPD subjects, with prefrontal hyperactivation and amygdaloidal hypoactivation [48],[16], and a lower functional activity in temporal regions [49][51]. A recent work by Sierk et al. [51] observed significantly less fractional anisotropy between the right middle temporal gyrus (MTG) and the right supramarginal gyrus (SMG) in subjects with DPD, as found in other studies [52],[53]. A lower structural connectivity was also observed between the left temporal pole and the left superior temporal gyrus. In addition, the severity of dissociative symptoms is negatively correlated with the fractional anisotropy values of this connection.

    SMG is a fundamental region for the integration of sensory information, due to its involvement in receiving afferents from visual, auditory, somatosensory and limbic structures, and has been associated with cross-modal spatial attention [54]. MTG appears to be important for conceptual processing [55],[56] and transmodal integration [57],[58]. Furthermore, the left temporal pole plays an important role in creating associations between different functions [59] and the left superior temporal gyrus is involved in auditory processing [60]. Partial and temporal regions are partially included in TPJ, so it is possible to hypothesize their functional involvement in the integration of information for a correct perception of the body self. As evidence of what has been discussed, we have shown above that TMS stimulation of these regions leads to an improvement in the symptoms of DPD [43][46]. Similarly, a stimulation of TPJ in healthy subjects induces bodily illusion. To date, it remains unclear how the fronto-limbic imbalance, that is a core feature in patients with DPD, is associated with dysfunction of the TPJ.

    In the context of TMS stimulation protocol targeting medial prefrontal cortex (mPFC), Gruberger and colleagues [61] also reported dissociative and detachment phenomena after the induction of the functional lesions: indeed, the use of large H coil used by the authors could have produced an alteration of the ongoing sense of self by indirectly involving the TPJ. It is worth nothing that both TPJ and mPFC are functionally connected within Default Mode Network, that play a pivotal role in self-introspective and self-mentalization activity [62].

    It is important to underline that depersonalization and derealization symptoms are not exclusively present only in the DPD, but also in multiple psychopathological disorders such as anxiety disorders, mood disorders, post-traumatic stress disorder and epilepsy. Moreover, transient episodes of depersonalization and derealization are often experienced by non-clinical populations. For these reasons, the use of methods such as TMS on TPJ can prove to be a valid treatment tool for the improvement of many clinical disorders.

    In conclusion, there are several limitations to be addressed regarding the correct assessment of the role of the TPJ related to self-perception. TPJ is a network with a wide range of afferences; therefore, its position, structure and parcellation lead to a difficult comprehension of its functions. Other challenges encountered were the following: low number of studies using TMS on TPJ in patients with DPD; small sample size; moderate heterogeneity of paradigms between studies; limited data reported and limited statistical significance.

    Furthermore, we were not able to define the number of TMS sessions sufficient to induce effects on symptoms. Future studies, should use protocols that include control groups and follow-up sessions, more reliable measures and both qualitative and quantitative assessments.

    To our knowledge, this review is the first focusing on the use of TMS on TPJ in DPD. This review shows the relationship between DPD with TPJ and the efficacy of TMS in the treatment of these disorders. Furthermore, this review is the first focusing on use of TMS on TPJ for inducing disembodiment. These data are a first step towards a greater understanding of possible treatments to be used in embodiment disorders. It is important to highlight that despite the promising approaches investigated so far, due to the challenges encountered, conclusions on the effectiveness of the reported methods are premature.

    [1] Fujita T, Inoue K, Yamamoto S, et al. (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47: 208-215.
    [2] Fujita T, Inoue K, Yamamoto S, et al. (1994) Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyruiocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2- hydroxy- methyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives. J Antibiot 47: 216-224.
    [3] Fujita T, Yoneta M, Hirose R, et al. (1995) Simple compounds, 2-alkyl-2- amino-1,3-propane-diols have potent immunosuppressive activity. Bioorg Med Chem Lett 5: 847-852. doi: 10.1016/0960-894X(95)00126-E
    [4] Adachi K, Kohara T, Nakao N, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immuno- suppressant, FTY720. Bioorg Med Chem Lett 5: 853-856. doi: 10.1016/0960-894X(95)00127-F
    [5] Fujita T, Hirose R, Yoneta M, et al. (1996) Potent immunosuppressants, 2-alkyl-2- aminopropane-1,3-diols. J Med Chem 39: 4451-4459. doi: 10.1021/jm960391l
    [6] Kiuchi M, Adachi K, Kohara T, et al. (2000) Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem 43: 2946-2961. doi: 10.1021/jm000173z
    [7] Adachi K, Chiba K (2008) FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem 1: 11-23.
    [8] Chiba K, Adachi K (2012) Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis. Pharmaceuticals 5:514-528. doi: 10.3390/ph5050514
    [9] Chiba K, Hoshino Y, Suzuki C, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 28: 1056-1059.
    [10] Hoshino Y, Suzuki C, Ohtsuki M, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 28: 1060-1061.
    [11] Kawaguchi T, Hoshino Y, Rahman F, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 28: 1062-1063.
    [12] Chiba K. (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108: 308-319. doi: 10.1016/j.pharmthera.2005.05.002
    [13] Matsuura M, Imayoshi T, Chiba K, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 49: 404-410. doi: 10.1007/s000110050608
    [14] Chiba K, Yanagawa Y, Masubuchi Y, et al. (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160: 5037-5044.
    [15] Yanagawa Y, Sugahara K, Kataoka H, et al. (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 160: 5493-5499.
    [16] Brinkmann V. Pinschewer D, Chiba K, Feng L (2000) FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 21: 49-52. doi: 10.1016/S0165-6147(99)01419-4
    [17] Brinkmann V, Davis MD, Heise CE, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457. doi: 10.1074/jbc.C200176200
    [18] Mandala S, Hajdu R, Bergstrom J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349. doi: 10.1126/science.1070238
    [19] Matloubian M, Lo CG, Cinamon G, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360. doi: 10.1038/nature02284
    [20] Spiegel S, Milstien S (2007) Functions of the multifaceted family od sphingosine kinases and some dose relatives. J Biol Chem 282: 2125-2129. doi: 10.1074/jbc.R600028200
    [21] Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150. doi: 10.1038/nrm2329
    [22] Pyne S, Pyne N (2000) Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 88: 115-131. doi: 10.1016/S0163-7258(00)00084-X
    [23] Spiegel S (2000) Sphingosine 1-phosphate: A ligand for the EDG-1 family of G-protein-coupled receptors. Ann NY Acad Sci 905: 54-60.
    [24] Rivera J, Proia RL, Olivera A (2008) The alliance of shpingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8: 753-763. doi: 10.1038/nri2400
    [25] Spiegel S, Milstien S (2011) The outs and the ins of shingosine-1-phosphate in immunity. Nat Rev Immunol 11: 403-415. doi: 10.1038/nri2974
    [26] Paugh SW, Payne SG, Barbour SE, et al. (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189-193. doi: 10.1016/S0014-5793(03)01168-2
    [27] Chiba K, Matsuyuki H, Maeda Y, Sugahara K (2006) Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 3: 11-19.
    [28] Maeda Y, Matsuyuki H, Shimano K, et al. (2007) Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 178: 3437-3446. doi: 10.4049/jimmunol.178.6.3437
    [29] Pham TH, Okada T, Matloubian M, et al. (2008) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28: 122-133. doi: 10.1016/j.immuni.2007.11.017
    [30] Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127-159. doi: 10.1146/annurev.immunol.23.021704.115628
    [31] Mitra P, Oskeritzian CA, Payne SG, et al. (2006) Role of ABCC1 in export of sphingosine- 1-phosphate from mast cells. Proc Natl Acad Sci USA 103: 16394-16399. doi: 10.1073/pnas.0603734103
    [32] Nishi T, Kobayashi N, Hisano Y et al. (2014) Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 1841: 759-765. doi: 10.1016/j.bbalip.2013.07.012
    [33] Mechtcheriakova D, Wlachos A, Sobanov J, et al. (2007) Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19: 748-760. doi: 10.1016/j.cellsig.2006.09.004
    [34] Peest U, Sensken SC, Andréani P, et al. (2008) S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 104: 756-772. doi: 10.1002/jcb.21665
    [35] Zhao Y, Kalari SK, Usatyuk PV, et al. (2007) Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1. J Biol Chem 282: 14165-14177. doi: 10.1074/jbc.M701279200
    [36] Pappu R, Schwab SR, Cornelissen I, et al. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298. doi: 10.1126/science.1139221
    [37] Schwab SR, Pereira JP, Matloubian M, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309: 1735-1739. doi: 10.1126/science.1113640
    [38] Lo CG, Xu Y, Proia RL, Cyster JG (2005) Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 201: 291-301. doi: 10.1084/jem.20041509
    [39] Kiuchi M, Adachi K, Tomatsu A, et al. (2005) Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg. Med. Chem 13: 425-432. doi: 10.1016/j.bmc.2004.10.008
    [40] Matsuyuki H, Maeda Y, Yano K, et al. (2006) Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. Cell Mol Immunol 3: 429-437.
    [41] Oo ML, Thangada S, Wu MT, et al. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089. doi: 10.1074/jbc.M610318200
    [42] Ladi E, Yin X, Chtanova T, Robey EA (2006) Thymic microenvironments for T cell differentiation and selection. Nat Immunol 7: 338-343. doi: 10.1038/ni1323
    [43] Drennan MB, Elewaut D, Hogquist KA (2009) Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond. Eur J Immunol 39: 925-930. doi: 10.1002/eji.200838912
    [44] Kato S, Schoefl GI (1989) Microvasculature of normal and involuted mouse thymus. Light- and electron-microscopic study. Acta Anat (Basel) 135: 1-11.
    [45] Kato S (1997) Thymic microvascular system. Microsc Res Tech 38: 287-299. doi: 10.1002/(SICI)1097-0029(19970801)38:3<287::AID-JEMT9>3.0.CO;2-J
    [46] Mori K, Itoi M, Tsukamoto N, et al. (2007) The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma. Int Immunol 19: 745-753. doi: 10.1093/intimm/dxm041
    [47] Zachariah MA, Cyster JG (2010) Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science 328: 1129-1135. doi: 10.1126/science.1188222
    [48] Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30: 69-94. doi: 10.1146/annurev-immunol-020711-075011
    [49] Yagi H, Kamba R, Chiba K, et al. (2000) Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 30:1435.
    [50] Maeda Y, Yagi H, Takemoto K, et al. (2014) S1P lyase in thymic perivascular space promotes egress of mature thymocytes via up-regulation of S1P receptor 1. Int Immunol 26: 245-255. doi: 10.1093/intimm/dxt069
    [51] Allende ML, Dreier JL, Mandala S, Proia RL (2004) Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279: 15396-15401. doi: 10.1074/jbc.M314291200
    [52] Saba JD, Hla T (2004) Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 94: 724-734. doi: 10.1161/01.RES.0000122383.60368.24
    [53] Breart B, Ramos-Perez WD, Mendoza A, et al. (2011) Lipid phosphate phosphatase 3 enables efficient thymic egress. J Exp Med 208: 1267-1278. doi: 10.1084/jem.20102551
    [54] Vogel P, Donoviel MS, Read R, et al. (2009) Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4:e4112.
    [55] Borowsky AD, Bandhuvula P, Kumar A, , et al. (2012) Sphingosine-1-phosphate lyase expression in embryonic and adult murine tissues. J Lipid Res 53: 1920-1931. doi: 10.1194/jlr.M028084
    [56] Suzuki S, Li XK, Enosawa S, and Shinomiya T (1996) A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 89:518-23. doi: 10.1046/j.1365-2567.1996.d01-777.x
    [57] Nagahara Y, Enosawa S, Ikekita M, et al. (2000) Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 48:75-85. doi: 10.1016/S0162-3109(00)00181-8
    [58] Luo ZJ, Tanaka T, Kimura F, Miyasaka M (1999) Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology. 41:199-207. doi: 10.1016/S0162-3109(99)00004-1
    [59] Sugito K, Koshinaga T, Inoue M, et al. (2005) The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs. Surg Today 35:662-7. doi: 10.1007/s00595-005-3011-x
    [60] Maeda Y, Seki N, Sato N, et al. (2010) Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol 22: 515-525. doi: 10.1093/intimm/dxq036
    [61] Webb M, Tham CS, Lin FF, et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153: 108-121. doi: 10.1016/j.jneuroim.2004.04.015
    [62] Kataoka H, Sugahara K, Shimano K, et al. (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2: 439-448.
    [63] Balatoni B, Storch MK, Swoboda EM, et al. (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74: 307-316. doi: 10.1016/j.brainresbull.2007.06.023
    [64] Foster CA, Howard LM, Schweitzer A, et al. (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469-475. doi: 10.1124/jpet.107.127183
    [65] Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105. doi: 10.1016/j.pharmthera.2007.04.006
    [66] Chiba K, Kataoka H, Seki N, et al. (2011) Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 11: 366-372. doi: 10.1016/j.intimp.2010.10.005
    [67] Langrish CL, Chen Y, Blumenschein WM, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240. doi: 10.1084/jem.20041257
    [68] Komiyama Y, Nakae S, Matsuki T, et al. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573. doi: 10.4049/jimmunol.177.1.566
    [69] Stromnes IM, Cerretti LM, Liggitt D, et al. (2008) Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med 14: 337-342. doi: 10.1038/nm1715
    [70] Seki N, Maeda Y, Kataoka H, et al. (2013) Role of sphingosine 1-phosphate (S1P) receptor 1 in experimental autoimmune encephalomyelitis. I. S1P-S1P1 axis induces migration of Th1 and Th17 cells. Pharmacology & Pharmacy 4: 628-637.
    [71] Brinkmann V (2009) FTY720 (fingolimod) in Multiple Sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158: 1173-1182. doi: 10.1111/j.1476-5381.2009.00451.x
    [72] Choi JW, Gardell SE, Herr DR, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108: 751-756. doi: 10.1073/pnas.1014154108
    [73] Seki N, Kataoka H, Sugahara K, et al. (2013) Role of sphingosine 1-phosphate (S1P) receptor 1 in experimental autoimmune encephalomyelitis. II. S1P-S1P1 axis induces pro-inflammatory cytokine production in astrocytes. Pharmacology & Pharmacy 4: 638-646.
    [74] Matsuura M, Imayoshi T, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 22: 323-331. doi: 10.1016/S0192-0561(99)00088-0
    [75] Tsunemi S, Iwasaki T, Kitano S, et al. (2010) Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol 136: 197-204. doi: 10.1016/j.clim.2010.03.428
    [76] Okazaki H, Hirata D, Kamimura T, et al. (2002) Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716.
    [77] Wenderfer SE, Stepkowski SM, Braun MC (2008) Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int 74: 1319-1326. doi: 10.1038/ki.2008.396
    [78] Alperovich G, Rama I, Lloberas N, et al. (2007) New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24. doi: 10.1177/0961203306073136
    [79] Mizushima T, Ito T, Kishi D, et al. (2004) Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10: 182-192. doi: 10.1097/00054725-200405000-00002
    [80] Deguchi Y, Andoh A, Yagi Y, et al (2006) The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep 16: 699-703.
    [81] Daniel C, Sartory N, Zahn N, et al. (2007) FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 178: 2458-2468. doi: 10.4049/jimmunol.178.4.2458
    [82] Radi ZA, Heuvelman DM, Masferrer JL, et al (2011) Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model. Dig Dis Sci 56: 2283-2291. doi: 10.1007/s10620-011-1628-8
    [83] Budde K, Schmouder RL, Brunkhorst R, et al. (2002) Human first trail of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073-1083.
    [84] Budde K, Schmouder RL, Nashan B, et al. (2003) Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 3: 846-854. doi: 10.1034/j.1600-6143.2003.00130.x
    [85] Kahan BD, Karlix JL, Ferguson RM, et al. (2003) Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76: 1079-1084. doi: 10.1097/01.TP.0000084822.01372.AC
    [86] Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153-187. doi: 10.1146/annurev.iy.10.040192.001101
    [87] Kornek B, Storch MK, Weissert R, et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: 267-276. doi: 10.1016/S0002-9440(10)64537-3
    [88] Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
    [89] Goodkin DE, Reingold S, Sibley W, et al. (1999) Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Ann Neurol 46: 132-134.
    [90] Kappos L, Antel J, Comi G, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Eng J Med 355: 1124-1140. doi: 10.1056/NEJMoa052643
    [91] Mehling M, Lindberg R, Raulf F, et al. (2011) Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75: 403-410.
    [92] Kappos L, Radue EW, O’Connor P, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401. doi: 10.1056/NEJMoa0909494
    [93] Saida T, Kikuchi S, Itoyama Y, et al. (2012) A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 18:1267-1277.
    [94] Kira J, Itoyama Y, Kikuchi S, et al. (2014) Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology 14: 21. doi: 10.1186/1471-2377-14-21
    [95] Cohen JA, Barkhof F, Comi G, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415. doi: 10.1056/NEJMoa0907839
    [96] Deogracias R, Yazdani M, Dekkers MP, et al (2013) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA 109: 14230-14235.
    [97] Igarashi J, Erwin PA, Dantas AP, et al. (2003) VEGF induces S1P1 receptors in endothelial cells: implications for crosstalk between sphingolipid and growth factors receptors. Proc Natl Acad Sci USA 100: 10664-10669. doi: 10.1073/pnas.1934494100
    [98] Sanna MG, Liao J, Jo E, et al. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848. doi: 10.1074/jbc.M311743200
    [99] Shimizu H, Takahashi M, T. Kaneko T et al. (2005) KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111: 222-229. doi: 10.1161/01.CIR.0000152101.41037.AB
    [100] Hamada M, Nakamura M, Kiuchi M et al. (2010) Removal of sphingosine 1-phosphate receptor-3 (S1P3) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P1 agonists with reduced effect on heart rate. J Med Chem 53: 3154-3168. doi: 10.1021/jm901776q
    [101] Hale JJ, Lynch, CL, Neway WE, et al. (2004) A unique utilization of high throughput screening leads to afford selective, orally bioavailable 1-benzyl-3-carboxyazetidine S1P1 receptor agonists. J Med Chem 47: 6662-6665. doi: 10.1021/jm0492507
    [102] Vachal P, Toth LM, Hale JJ, et al. (2006) Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorg Med Chem Lett 16: 3684-3687. doi: 10.1016/j.bmcl.2006.04.064
    [103] Foss FW, Snyder AH, Davis MD, et al. (2007) Synthesis and biological evaluation of gammma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 15: 663–677.
    [104] Hanessian S, Charron G, Billich A, et al. (2007) Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett 17: 491-494. doi: 10.1016/j.bmcl.2006.10.014
    [105] Pan S, Gray NS, Gao W, et al. (2013) Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett 4: 333-337. doi: 10.1021/ml300396r
    [106] Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167: 1035-1047. doi: 10.1111/j.1476-5381.2012.02061.x
    [107] Selmaj K, Li DK, Hartung HP, et al. (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12: 756-767. doi: 10.1016/S1474-4422(13)70102-9
    [108] Biswal S, Veldandi UK, Derne C, et al. (2014) Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects. Int J Clin Pharmacol Ther Aug 27. [Epub ahead of print]
    [109] Olsson T, Boster A, Fernández O, et al (2014) Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 85: 1198-1208. doi: 10.1136/jnnp-2013-307282
    [110] Vaclavkova A, Chimenti S, Arenberger P, et al. (2014) Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet pii: S0140-6736: 60803-60805.
    [111] Mazurais D, Robert P, Gout B, et al. (2002) Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50: 661-670. doi: 10.1177/002215540205000507
    [112] Lukas S, Patnaude L, Haxhinasto S, et al. (2014) No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation. J Biomol Screen 19: 407-416. doi: 10.1177/1087057113502234
    [113] Oo ML, Chang SH, Thangada S, et al. (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121: 2290-2300. doi: 10.1172/JCI45403
    [114] Violin JD, Crombie AL, Soergel DG, et al. (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35: 308-316. doi: 10.1016/j.tips.2014.04.007
  • Reader Comments
  • © 2014 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(12664) PDF downloads(2072) Cited by(8)

Figures and Tables

Figures(5)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog